Switzerland presents an attractive opportunity for US biotech companies considering launching orphan drugs in Europe.

It’s the third-fastest country for reimbursing new medicines post-approval and recent regulatory changes look likely to speed this up even further.

Its regulatory independence from the EU, alongside its commitment to improving access to rare disease treatments, offers a unique opportunity.

In our exclusive guide we explore:

• the national regulatory bodies
• the steps involved in gaining market access in Switzerland
• the new regulatory framework
• pre-approval routes, including early access programs
• and the reasons why you may want to look at Switzerland for the launch of your orphan drugs in Europe.